Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease

被引:118
|
作者
Di Minno, Matteo Nicola Dario [1 ]
Russolillo, Anna [1 ]
Lupoli, Roberta [1 ]
Ambrosino, Pasquale [1 ]
Di Minno, Alessandro [1 ]
Tarantino, Giovanni [1 ]
机构
[1] Univ Naples Federico II, Dept Clin & Expt Med, Reg Reference Ctr Coagulat Disorders, I-80131 Naples, Italy
关键词
Hepatic steatosis; Non-alcoholic fatty liver disease; Omega-3 polyunsaturated fatty acids; Animal models; ACTIVATED-RECEPTOR-ALPHA; ELEMENT-BINDING PROTEIN-1; AMELIORATE HEPATIC STEATOSIS; OXIDATIVE STRESS; INSULIN-RESISTANCE; GENE-EXPRESSION; ACID REGULATION; MURINE MODEL; MOLECULAR-MECHANISMS; METABOLIC SYNDROME;
D O I
10.3748/wjg.v18.i41.5839
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) has been recognized as a major health burden. It is the most important cause of chronic liver disease and a major independent cardiovascular risk factor. Lacking a definite treatment for NAFLD, a specific diet and an increase in physical activity represent the most commonly used therapeutic approaches. In this review, major literature data about the use of omega-3 polyunsaturated fatty acids (n-3 PUFAs) as a potential treatment of NAFLD have been described. n-3 PUFAs, besides having a beneficial impact on most of the cardio-metabolic risk factors (hypertension, hyperlipidemia, endothelial dysfunction and atherosclerosis) by regulating gene transcription factors [i.e., peroxisome proliferator-activated receptor (PPAR) alpha, PPAR gamma, sterol regulatory element-binding protein-1, carbohydrate responsive element-binding protein], impacts both lipid metabolism and on insulin sensitivity. In addition to an enhancement of hepatic beta oxidation and a decrease of the endogenous lipid production, n-3 PUFAs are able to determine a significant reduction of the expression of pro-inflammatory molecules (tumor necrosis factor-alpha and interleukin-6) and of oxygen reactive species. Further strengthening the results of the in vitro studies, both animal models and human intervention trials, showed a beneficial effect of n-3 PUFAs on the severity of NAFLD as expressed by laboratory parameters and imaging measurements. Despite available results provided encouraging data about the efficacy of n-3 PUFAs as a treatment of NAFLD in humans, well-designed randomized controlled trials of adequate size and duration, with histological endpoints, are needed to assess the long-term safety and efficacy of PUFA, as well as other therapies, for the treatment of NAFLD and non-alcoholic steatohepatitis patients. It is worthwhile to consider that n-3 PUFAs cannot be synthesized by the human body and must be derived from exogenous sources (fish oil, flaxseeds, olive oil) which are typical foods of the Mediterranean diet, known for its beneficial effects in preventing obesity, diabetes and, in turn, cardiovascular events. According to these data, it is important to consider that most of the beneficial effects of n-3 PUFAs can also be obtained by an equilibrate nutrition program. (C) 2012 Baishideng. All rights reserved.
引用
收藏
页码:5839 / 5847
页数:9
相关论文
共 50 条
  • [1] Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease
    Matteo Nicola Dario Di Minno
    Anna Russolillo
    Roberta Lupoli
    Pasquale Ambrosino
    Alessandro Di Minno
    Giovanni Tarantino
    [J]. World Journal of Gastroenterology, 2012, (41) : 5839 - 5847
  • [2] The significance of omega-3 fatty acids in the treatment of non-alcoholic fatty liver disease
    Anna, Mako Rebeka
    Anna, Egresi
    Anna, Blazovics
    Reka, Oszlanyi
    Krisztina, Hagymasi
    [J]. ORVOSI HETILAP, 2023, 164 (33) : 1294 - 1299
  • [3] Omega-3 polyunsaturated fatty acids: A pilot trial in non-alcoholic fatty liver disease
    Spadaro, L.
    Magliocco, O.
    Spampinato, D.
    Piro, S.
    Oliveri, C.
    Alagona, C.
    Papa, G.
    Rabuazzo, A. M.
    Purrello, F.
    [J]. JOURNAL OF HEPATOLOGY, 2006, 44 : S264 - S264
  • [4] Role of nitric oxide in the treatment of non-alcoholic fatty liver by omega-3 fatty acids
    Beyazit, Y.
    Purnak, T.
    Kekilli, M.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (02) : 303 - 304
  • [5] Omega-3 polyunsaturated fatty acids: A specific liver drug for non-alcoholic fatty liver disease (NAFLD)
    Xin, Yong-Ning
    Xuan, Shi-Ying
    Zhang, Jian-Hua
    Zheng, Ming-Hua
    Guan, Hua-Shi
    [J]. MEDICAL HYPOTHESES, 2008, 71 (05) : 820 - 821
  • [6] A CLINICAL TRIAL INVESTIGATING THE EFFECT OF OMEGA-3 FATTY ACIDS ON NON-ALCOHOLIC FATTY LIVER DISEASE
    Masterton, G.
    Shams, A.
    Walsh, J.
    Tuck, S.
    Plevris, J.
    Hayes, P.
    [J]. GUT, 2015, 64 : A256 - A256
  • [7] Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action
    Scorletti, Eleonora
    Byrne, Christopher D.
    [J]. MOLECULAR ASPECTS OF MEDICINE, 2018, 64 : 135 - 146
  • [8] Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial
    Wojciech Janczyk
    Piotr Socha
    Dariusz Lebensztejn
    Aldona Wierzbicka
    Artur Mazur
    Joanna Neuhoff-Murawska
    Pawel Matusik
    [J]. BMC Pediatrics, 13
  • [9] Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial
    Janczyk, Wojciech
    Socha, Piotr
    Lebensztejn, Dariusz
    Wierzbicka, Aldona
    Mazur, Artur
    Neuhoff-Murawska, Joanna
    Matusik, Pawel
    [J]. BMC PEDIATRICS, 2013, 13
  • [10] Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease
    Masterton, G. S.
    Plevris, J. N.
    Hayes, P. C.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (07) : 679 - 692